Rising antibiotic resistance has reduced the effectiveness of standard Helicobacter pylori triple therapy, highlighting the need for more potent acid suppression strategies. Tegoprazan, a novel potassium-competitive acid blocker, offers faster and sustained acid inhibition compared to PPIs. To address this, a study evaluated the efficacy and safety of two tegoprazan dosing regimens (50 mg and 100 mg) versus lansoprazole-based triple therapy in 564 patients with H. pylori infection.
The study found eradication rates of 86.0% with tegoprazan 50 mg (TAC1), 85.5% with tegoprazan 100 mg (TAC2), and 78.7% with lansoprazole 30 mg (LAC), with both tegoprazan-based regimens meeting non-inferiority criteria. In clarithromycin-resistant infections, eradication rates were 47.8% (TAC1), 50.0% (TAC2), and 35.5% (LAC), though differences were not statistically significant. Safety profiles were…
